Segment Data (Tables)

3 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Business Segment

Selected information by reportable segment was as follows:

	Three Months Ended
	March 31, 2017			March 25, 2016
Net sales:
Specialty Brands	$	557.2		$	535.0
Specialty Generics	238.6			264.4
Net sales of reportable segments	795.8			799.4
Other (1)	15.1			16.4
Net sales	$	810.9		$	815.8
Operating income:
Specialty Brands	$	275.0		$	260.9
Specialty Generics	76.2			98.9
Segment operating income	351.2			359.8
Unallocated amounts:
Corporate and unallocated expenses (2)	(67.2		)	(25.4		)
Intangible asset amortization	(175.1		)	(175.0		)
Restructuring and related charges, net (3)	(18.7		)	(10.1		)
Non-restructuring impairment charges	—			(16.9		)
Operating income	$	90.2		$	132.4

(1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.

(2) Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(3) Includes restructuring-related accelerated depreciation.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments are as follows:

	Three Months Ended
	March 31, 2017		March 25, 2016
Acthar	$	271.8	$	248.4
Inomax	128.4		115.5
Ofirmev	73.4		71.1
Therakos immunotherapy	51.2		50.2
Hemostasis products	13.1		11.4
Other	19.3		38.4
Specialty Brands	557.2		535.0
Hydrocodone (API) and hydrocodone-containing tablets	30.3		40.8
Oxycodone (API) and oxycodone-containing tablets	22.1		37.9
Methylphenidate ER	23.7		24.6
Other controlled substances	107.4		121.9
Other products	55.1		39.2
Specialty Generics	238.6		264.4
Other (1)	15.1		16.4
Net sales	$	810.9	$	815.8

(1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.